Drug Discovery Partnership

AFTD has formed a partnership with the Alzheimer’s Drug Discovery Foundation (ADDF) of New York to fund the first ever grants for FTD drug discovery. During each year of the partnership, AFTD contributes $100,000 and ADDF contributes $200,000 to fund researchers who worked to bridge the gap that exists between basic research in the laboratory, where the goal is to understand the fundamental biological processes that have gone awry, and development of a new therapeutic for clinical testing. 

Recipients of the 2013 funding cycle are as follows:

Nigel Cairns, Ph.D.
Washington University, St. Louis
Restoring progranulin in frontotemporal disease

Jeffrey Rothstein, M.D., Ph.D.
Johns Hopkins University, School of Medicine
Development of Antisense therapy and Therapeutic biomarker for C9orf72 FTD/ALS mutation patients

W. Haung Yu, Ph.D.
Columbia University Medical Center
Development of small molecule enhancers of autophagy for the clearnace of protein aggregates and treatment of FTD

For more information on any of these 2013 projects, click here.

Recipients of the 2012 funding cycle are as follows:

Adam Boxer, M.D., Ph.D.
University of California, San Francisco
Biomarker optimization for progranulin trials

William Seeley, M.D.
University of California, San Francisco
Dynamic disease – monitoring network biomarkers for tracking frontotemporal dementia

Charlotte Teunissen, Ph.D.
VU University Medical Center, The Netherlands
Identification of novel discriminatory CSF biomarkers for different FTD subtypes by protemics

For more information on any of these 2012 projects, click here.

Recipients of the 2011 funding cycle are as follows:

William Hu, MD, Ph.D. 
Emory University School of Medicine, Atlanta, Georgia
CSF Biomarkers of FTLD-TDP and FTLD-Tau – A Multi-Center Study

Allen Roses, M.D.
Duke Center for Drug Discovery, Durham, North Carolina
Fine-mapping of genetic biomarkers that facilitate the acceleration of drug discovery for frontotemporal dementias

Marcel M. Verbeek, Ph.D., M.Sc.
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
TDP-43 and tau as cerebrospinal fluid biomarkers to discriminate frontotemporal dementia subtypes

Victor Villemagne, M.D.
University of Melbourne, Melbourne, Australia
[18F]-THK523, a novel in vivo tau imaging agent

For more information on any of these 2011 projects, click here.

Recipients of the 2010 funding cycle are as follows:

Philip Van Damme, M.D., Ph.D.
VIB, Leuven University, Leuven, Belgium
Drug discovery for progranulin-mediated frontotemporal lobar degeneration

Einar M. Sigurdsson, Ph.D.
New York University School of Medicine, New York, New York
Passive Immunotherapy for Frontotemporal Dementia

W. Haung Yu, Ph.D.
Taub Institute – Columbia University, New York, New York
Tau Clearance by Autophagy

For more information on any of these 2010 projects, click here.

Recipients of the 2009 funding cycle are as follows:

Gabriela Chiosis, Ph.D.
Memorial Sloan-Kettering Cancer Center, New York, New York
Hsp90 inhibitors in tauopathies: in vivo pre-clinical development

Adam Boxer, M.D. Ph.D.
University of California  – San Francisco
A Pilot Clinical Trial of NAP (AL-108) for Corticobasaldegeneration and
Frontotemporal Lobar Degeneration with Predicted Corticobasal Degeneration Pathology

Virginia M.-Y. Lee, Ph.D.
University of Pennsylvania, Philadelphia, Pennsylvania
Frontotemporal Lobar Degeneration (FTLD) Biomarker Assays

For more information on any of these 2009 projects, click here.

Recipients of the 2008 funding cycle are as follows:

David Vocadlo, Ph.D.
Assistant Professor of Chemistry
Simon Fraser University, British Columbia, Canada
Optimization of pharmacokinetic and pharmacodynamic properties of a small molecule o-glycosylation inhibitor for treatment of frontotemporal dementia

$ 65,000
Ben Bahr, Ph.D.
Associate Professor of Pharmaceutical Sciences, University of Connecticut
In vitro testing of new lysosomal modulatory drugs for reducing tau aggregates in a hippocampal slice model

$ 50,000
Larry Baum, Ph.D.
Assistant Professor of Medicine and Therapeutics
Chinese University, Hong Kong
Testing 17-AAG for treating frontotemporal dementia

$ 85,000
Tara Spires-Jones, Ph.D.
Instructor of Neuroscience
Harvard Medical School, Boston, Massachusettes
Sirtuins as modifiers of neurodegeneration is a mouse model of frontotemporal dementia

For more information on any of these 2008 projects, click here.